Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements

Rhea-AI Summary

Altamira Therapeutics (OTCID:CYTOF) will release its annual report and financial statements for the fiscal year ended December 31, 2025 on March 31, 2026 at 9:00 AM EDT. The release is expected to include audited financial statements and related disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMILTON, BM / ACCESS Newswire / March 24, 2026 / Altamira Therapeutics ("Altamira" or the "Company") (OTCID:CYTOF) today announced that it will release its annual report and financial statements for the fiscal year ended December 31, 2025 on March 31, 2026 at 9 am EDT.

About Altamira Therapeutics
Altamira Therapeutics is developing and supplying peptide-based nanoparticle technologies for efficient nucleic acid delivery (xPhore^™ platform). The versatile delivery platform is suited for different nucleic acid modalities, including siRNA, mRNA, circRNA, as well as DNA, and made available to pharma or biotech companies through out-licensing. The Company has two proprietary flagship programs based on xPhore and siRNA payloads: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. In addition, Altamira holds a 49% stake in Altamira Medica AG, which commercializes Bentrio, an OTC nasal spray for allergic rhinitis, and owns several assets for CNS indications which it intends to partner / divest. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/

Investor Contact:

Hear@altamiratherapeutics.com

SOURCE: Altamira Therapeutics Ltd.

View the original press release on ACCESS Newswire

FAQ

When will Altamira Therapeutics (CYTOF) release its 2025 annual report?

Altamira will release its 2025 annual report on March 31, 2026 at 9:00 AM EDT. According to Altamira, the filing covers the fiscal year ended December 31, 2025 and will include audited financial statements and management discussion of results.

What documents will Altamira (CYTOF) publish on March 31, 2026?

Altamira will publish its annual report and financial statements for the year ended December 31, 2025. According to Altamira, the materials are expected to include audited financial statements, notes, and related management commentary and disclosures.

How can investors access Altamira Therapeutics (CYTOF) annual report on release day?

Investors can access the annual report when Altamira posts it publicly on March 31, 2026 at 9:00 AM EDT. According to Altamira, the report will be available via its investor relations channels and applicable public filing systems.

Does the March 31, 2026 release by Altamira (CYTOF) include audited statements?

Yes, the release is described as the annual report and financial statements for the fiscal year ended December 31, 2025. According to Altamira, the package is expected to contain audited financial statements and accompanying disclosures.

Will Altamira Therapeutics (CYTOF) provide commentary with the 2025 financials?

Altamira is expected to provide management discussion alongside the 2025 financial statements on March 31, 2026 at 9:00 AM EDT. According to Altamira, the release will include management commentary and explanatory notes to the financials.